Case report describing a patient with metastatic BRCA2-related prostate cancer, who was treated by cisplatin after becoming insensitive to androgen ablation. Cisplatin therapy resulted in normalization of prostate-specific antigen level and symptomatic relief for period of 8 months; docetaxel was administered after the disease progression, and also led to an evident tumor response. This evidence concerns the gene KLK3 and Familial prostate cancer.